Nakamura Masato, Maruyama Kentarou, Furukawa Junkou, Maruyama Naomi, Tanaka Junnichi, Katsumoto Yoshihiro, Yokouchi Hideoki, Nakaguchi Kazunori, Sue Fumiaki, Yoshihara Wataru
Dept. of Surgery, Suita Municipal Hospital.
Gan To Kagaku Ryoho. 2002 Oct;29(10):1823-8.
Five patients with inoperable advanced gastric cancer were treated with combination chemotherapy of TS-1 and cisplatin (CDDP). TS-1 of 80-120 mg/body/day was orally administered for 3 weeks followed by 2 drug-free weeks, and 60 mg/m2/day of CDDP was venally administered on Day 8. It was possible to evaluate all 5 patients for response and toxicity. Only low grade toxicities (Grade 1 or 2) of leukocytopenia, neutrocytopenia, anemia, nausea, diarrhea and stomatitis were seen. Four of 5 patients achieved a partial response, for a response rate of 80.0%. Stomach, liver, lymph node and peritoneal tumors responded to TS-1/CDDP. TS-1/CDDP therapy produces a high response in cases of gastric cancer, and it is useful as a neoadjuvant chemotherapy.
5例无法手术的晚期胃癌患者接受了替吉奥（TS-1）和顺铂（CDDP）联合化疗。替吉奥剂量为80-120mg/体/天，口服3周，随后停药2周，第8天静脉给予顺铂60mg/m²/天。对所有5例患者的疗效和毒性均进行了评估。仅观察到白细胞减少、中性粒细胞减少、贫血、恶心、腹泻和口腔炎等轻度毒性（1级或2级）。5例患者中有4例获得部分缓解，缓解率为80.0%。胃、肝、淋巴结和腹膜肿瘤对TS-1/CDDP有反应。TS-1/CDDP疗法对胃癌病例有较高的缓解率，作为新辅助化疗是有效的。
